Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 52-Week Low – Should You Sell?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s share price hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $731.80 and last traded at $733.47, with a volume of 31478 shares changing hands. The stock had previously closed at $740.97.

Analysts Set New Price Targets

A number of research firms have weighed in on REGN. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Oppenheimer dropped their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Evercore ISI dropped their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Royal Bank of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.90.

Regeneron Pharmaceuticals Trading Down 0.6 %

The firm has a market cap of $80.94 billion, a P/E ratio of 18.34, a price-to-earnings-growth ratio of 2.32 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s 50-day simple moving average is $855.40 and its 200 day simple moving average is $1,005.56.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Sachetta LLC raised its position in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Finally, Family Firm Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.